Back

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Management of comorbidities and outcomes in atrial fibrillation (2) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Yi-Heng Li

National Cheng Kung University Hospital, Tainan (Taiwan)

7 More presentations in this session

Presentation thumbnail
Effect of the longitudinal change in anemia status on clinical outcomes for patients with nonvalvular atrial fibrillation: analysis from the Hokuriku-Plus AF registry
Doctor T. Tsuda (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
Implications of renal function on adverse clinical events in patients with atrial fibrillation: a comparative analysis of VKA and NOAC therapy - Insights from the GLORIA-AF Registry Phase III
Doctor Y. Chen (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Risk of atrial fibrillation recurrence after new-onset transient episode during ST-elevation myocardial infarction
Doctor M. Demidova (Lund, SE) Professor P. Platonov (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Evaluation of concordance and association with clinical outcomes across eGFR values calculated with eight different formulas in a large cohort of european patients with atrial fibrillation.
Professor G. Boriani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Adherence to the Atrial Fibrillation Better Care (ABC) pathway and outcomes in patients with chronic kidney disease: A report from the APHRS-AF registry.
Doctor T. Bucci (Perugia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Management of comorbidities and outcomes in atrial fibrillation (2)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of statin and ezetimibe for the prevention of stroke in patients with atrial fibrillation
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
thumbnail
Congress Presentation
Decreased risk of cardiovascular events in patients with atrial fibrillation treated with lipid-lowering therapy: 2-year follow-up of the Global ETNA-AF program

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources